An Overview of Neuroendocrine Tumour Markers

被引:4
|
作者
Ozaslan, Ersin [1 ]
Diri, Halit [2 ]
Karaca, Halit [1 ]
Simsek, Yasin [2 ]
Bayram, Fahri [2 ]
机构
[1] Erciyes Univ, Fac Med, Dept Med Oncol, Kayseri, Turkey
[2] Erciyes Univ, Fac Med Endocrinol & Metab, Kayseri, Turkey
关键词
Neuroendocrine tumors; tumor markers; chromogranin A; neuron-specific enolase; 5-hydroxyindoleacetic acid;
D O I
10.4274/tjem.2422
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
As there are many different subtypes of neuroendocrine tumors (NETs), many kinds of markers are used for their diagnosis and follow-up. Most of these markers, such as calcitonin, catecholamines, 5-hydroxyindoleacetic acid (5-HIAA), insulin, gastrin, pancreatic polypeptide, and glucagon are specific to one subtype of NET. In addition, there are also general markers used in various NET subtypes; the most commonly used ones are chromogranin-A (CgA), neuron-specific enolase (NSE), and synaptophysin. The sensitivity and specificity levels of CgA are highest among all NET markers. However, specific markers, such as calcitonin in medullary thyroid carcinoma, insulin in insulinoma and cathecolamines in feocromocitoma are more useful than CgA. CgA is an auxiliary marker in cases with relapse or metastasis of such functional NETs. Carcinoid syndrome is characterized by serotonin hypersecretion with the other products and 5-HIAA level is used to determine the serotonin hypersecretion. Thus, 5-HIAA is the specific marker for carcinoid tumors which comprise two-thirds of all NETs.
引用
收藏
页码:132 / 136
页数:5
相关论文
共 50 条
  • [31] Neuroendocrine tumour of the urinary bladder
    Sharma, Gaurav
    Shergill, Kainaat
    Patil, Monish
    Radcliffe, Robert
    BMJ CASE REPORTS, 2025, 18 (01)
  • [32] A primitive neuroendocrine liver tumour?
    Cevenini, Monica
    Guidetti, Elena
    Galassi, Eleonora
    Ferrata, Martina
    Tomassetti, Paola
    Corinaldesi, Roberto
    CLINICAL MANAGEMENT ISSUES, 2012, 6 : 11 - 15
  • [33] Neuroendocrine tumor markers
    Lamberts, SWJ
    Hofland, LJ
    Nobels, FRE
    FRONTIERS IN NEUROENDOCRINOLOGY, 2001, 22 (04) : 309 - 339
  • [34] The role of alpha fetoprotein and human chorionic gonadotrophin-β as prognostic tumour markers in patients with neuroendocrine tumours
    Srirajaskanthan, R.
    Shah, T.
    Bhogal, M.
    Toumpanakis, C.
    Meyer, T.
    Noonan, A.
    Amin, T.
    Witney-Smith, C.
    Niroshan, S.
    Ben, W.
    Hochhauser, D.
    GUT, 2008, 57 : A68 - A69
  • [35] The first case of combined pancreatic neuroendocrine tumour and neuroendocrine carcinoma
    Lun, Tegan
    Rosty, Christophe
    Palamuthusingam, Pranavan
    JOURNAL OF SURGICAL CASE REPORTS, 2024, 2024 (12):
  • [36] Tumour markers - Introduction
    Abelev, GI
    Sell, S
    SEMINARS IN CANCER BIOLOGY, 1999, 9 (02) : 61 - 65
  • [37] Tumour endothelial markers
    Kopczynska, Ewa
    WSPOLCZESNA ONKOLOGIA-CONTEMPORARY ONCOLOGY, 2008, 12 (06): : 255 - 260
  • [38] Tumour markers in malignancies
    Lindblom, A
    Liljegren, A
    BMJ-BRITISH MEDICAL JOURNAL, 2000, 320 (7232): : 424 - 427
  • [39] Overview of neuroendocrine cells and tumors
    Lloyd, RV
    ENDOCRINE PATHOLOGY, 1996, 7 (04) : 323 - 328
  • [40] Mixed acinar neuroendocrine tumour: a rare case of pancreatic tumour
    Souka, E.
    Stanc, G.
    Galanopoulos, G.
    Karelis, L.
    Tzaida, O.
    Kontis, E.
    VIRCHOWS ARCHIV, 2022, 481 (SUPPL 1) : S242 - S242